[HTML][HTML] JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines
M Porcu, O Gielen, J Cools, K De Keersmaecker - Haematologica, 2009 - ncbi.nlm.nih.gov
M Porcu, O Gielen, J Cools, K De Keersmaecker
Haematologica, 2009•ncbi.nlm.nih.govCorrespondence: Norio Asou, MD, Department of Hematology, Kumamoto University School
of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan. Phone:+ 81.96. 373.5156, Fax:+
81.96. 363.5265. E-mail: ktcnasou@ gpo. kumamoto-u. ac. jp Citation: Iwanaga E, Nanri T,
Matsuno N, Kawakita T, Mitsuya H, and Asou N. A JAK2-V617F activating mutation in
addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t (8;
21)(q22; q22) acute myeloid leukemia. Haematologica 2009; 94: 433-435. doi …
of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan. Phone:+ 81.96. 373.5156, Fax:+
81.96. 363.5265. E-mail: ktcnasou@ gpo. kumamoto-u. ac. jp Citation: Iwanaga E, Nanri T,
Matsuno N, Kawakita T, Mitsuya H, and Asou N. A JAK2-V617F activating mutation in
addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t (8;
21)(q22; q22) acute myeloid leukemia. Haematologica 2009; 94: 433-435. doi …
Correspondence: Norio Asou, MD, Department of Hematology, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan. Phone:+ 81.96. 373.5156, Fax:+ 81.96. 363.5265. E-mail: ktcnasou@ gpo. kumamoto-u. ac. jp Citation: Iwanaga E, Nanri T, Matsuno N, Kawakita T, Mitsuya H, and Asou N. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t (8; 21)(q22; q22) acute myeloid leukemia. Haematologica 2009; 94: 433-435. doi: 10.3324/haematol. 13283
ncbi.nlm.nih.gov